Our Executive Team

With hundreds of years in combined research, drug development, & business management, our team is dedicated to accelerating wellness by producing the highest quality medicines that introduce global impact, positive outcomes, and deliver hope to those suffering from disease without answers. Join our movement!

Peter Lange

Co-Founder, CEO
Mr. Lange was one of the Co-founders of Reven and helped build the management team that currently drives the company.

Brian Denomme

Co-Founder, President
Mr. Denomme is a Co-Founder of Reven Pharmaceuticals with 30 years of International Executive Management experience.

Michael Volk

Co-Founder, Chief Strategy Officer
Mr. Volk has 24 years of International Executive Management experience, 20 of which have been in Healthcare, Pharmaceuticals, and Biotech.

Jeffrey B. Halverson

Chief Financial Officer
Mr. Halverson is known as an exceptional leader with effective management and team building skills. As an experienced banking executive, he has an impressive 30-plus year track record of opening and growing banking organizations.

Henk Van Wyk

Chief Scientist
Mr. Van Wyk brings over 40 years of experience in the pharmaceutical industry, including research, development, drug design and formulation.

Kevin McGovern

Kevin McGovern is the Chairman and CEO of McGovern Capital. Through McGovern Capital and its affiliates, he has co-founded over twenty-five (25) companies, six of which have become world/category leaders.

James Carlson, Pharm.D.

Executive VP of Development
Dr. Carlson has over 40 years in the pharmaceutical industry with expertise in product development. He co-founded and later owned PRACS Institute, Ltd., a contract research organization contracted by the drug industry for unbiased product evaluation for FDA submission.

Our Advisory Board

BA MB BChir MA MChir FRCS (Gen. Surg.) FRACS (Vascular Surgery) 

 📄 View Resume

Dr. Jürgen Lüders is currently employed at Saint Mary’s Mercy Health Neurosurgeon with a specialty in complex spine, epilepsy surgery and brain tumors.

 📄 View Resume

Professor Michael Davies has pioneered studies on the formation and subsequent reactions of oxidants and other reactive species with proteins, DNA and carbohydrates, and the role of such reactions in biological damage. His work on protein modification and the detection and reactions of reactive intermediates is recognized nationally and internationally and has resulted in a number of significant awards.

📄 View Resume

Conjoint Professor at the School of Medical Sciences Faculty of Medicine University of New South Wales Sydney, Professor Philip Barter has over 200 publications within the medical field.

📄 View Resume

Dr. Kowalski is board certified by the American Board of Neurological Surgery and is a Fellow of both the American Association of Neurological Surgeons and the American College of Surgeons. His practice encompasses all aspects of cranial and spinal surgery with particular emphasis on motion preservation technologies, minimally invasive surgery (MIS) techniques, and spinal instrumentation.

📄 View Resume

Specializing in Melanoma Oncology, Dr. Woodman has a board certification from The American Board of Internal Medicine.

📄 View Resume